The half that did nothing

Growth hormone does several different things at once: it grows tissue, it raises IGF-1, it pushes glucose up, and — the part this molecule cares about — it mobilizes fat. AOD-9604 is the tail end of that hormone, the C-terminal fragment hGH(176-191), isolated on a clean and appealing theory: that the fat-burning lives in this fragment, and can be cut away from everything else GH does. A fat-loss drug with none of growth hormone’s growth, no IGF-1 rise, no glucose problem.

That is a move this reference admires elsewhere. It is exactly what KPV does with α-MSH’s anti-inflammatory clause, and what ARA-290 does with erythropoietin’s tissue-protective one: keep the clause you want, drop the rest. AOD-9604 is the same design — and the instructive case where it did not pay off. Bullish on the method, sceptical on this result.

In the narrow technical sense, the split succeeded. In obese mice, AOD-9604 induced weight loss and raised lipolytic activity, apparently by engaging the β3-adrenergic pathway — the main fat-burning receptor on the fat cell — and the effect tracked with β3-adrenergic receptor expression (Heffernan et al., Endocrinology, 2001). Just as importantly, it did not carry growth hormone’s liabilities: no IGF-1 rise, and none of the insulin-sensitivity harm chronic GH can cause.

So the engineering brief was met. The fragment really had been separated from the rest of GH biology — you could give it and not get growth signaling or a glucose penalty. On the strength of that, and real rodent fat-loss data, it looked like a genuine candidate. The question was whether the kept clause would still say something in a human being.

It did not. In controlled human obesity trials, AOD-9604 failed to produce significant weight loss over placebo, and its development as a weight-loss drug was discontinued. The lipolysis that was robust in a mouse’s fat cells simply did not translate into meaningful fat loss in a person. The separation had worked and the kept half turned out to do nothing useful — you had cleanly isolated a clause that, in humans, said almost nothing.

And yet AOD-9604 did not disappear. It lives on in the research-peptide and cosmetic markets, marketed for fat loss on exactly the lipolytic story its own pivotal trial failed to support — the rodent mechanism and the appealing “GH fat fragment” framing doing the work that the human data won’t. It is the cleanest small example of the gap this site keeps flagging between a molecule’s mechanism and its proven effect: the first can be real and the second absent, and a marketplace will happily sell the first as if it were the second.

Set it beside its successful cousins and the contrast is the whole point. KPV kept a clause that still works; ARA-290 kept one whose mechanism is elegant and whose clinic is merely unproven. AOD-9604 kept a clause that, when finally tested properly in humans, was hollow. Three applications of the same smart design, three different verdicts — and only this one has a negative trial sitting under the claim.

• AOD-9604 is GH's lipolytic fragment. The C-terminal hGH(176-191) tail, isolated to keep growth hormone's fat-burning while dropping its growth, IGF-1 and glucose actions — a 'keep one clause' design.
• The separation genuinely worked. In mice it drove lipolysis via the β3-adrenergic pathway, with no IGF-1 rise and no insulin-sensitivity harm. The fat-metabolism clause was cut cleanly from the rest.
• But human obesity trials failed. Controlled trials showed no significant weight loss over placebo; development as a weight-loss drug was discontinued. The rodent effect didn't translate.
• Mechanism is not proof. A clean fragment of a fat-burning hormone is not a fat-burning drug. The separation succeeded and the kept half did nothing useful in people.
• It persists on claims the data don't support. AOD-9604 is still sold for fat loss on its mechanism story — the sharpest small case of marketing running ahead of a negative trial.